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Summary: We studied six different antisera to bovine or porcine parathyrin (parathyroid hormone, PTH), produced
in rabbit, guinea pigs, sheep or goat, two of which are commercially available. These antisera were characterized
with regard to species specificity, affinity and their ability to identify patients with primary hyperparathyroidism.
In this heterologous radioimmunoassay system in which [125I]parathyrin is used as a tracer, some cross-reactivity of
the antisera to the hormone or hormone fragments present in human serum was demonstrated. However, there is
some overlap of serum immunoreactive parathyrin in patients with or without primary hyperparathyroidism. The
results of this and other studies illustrate the necessity for a homologous radioimmunoassay for human parathyrin.
Radioimmunoassay fur Parathyrin: Charakterisierung von sechs verschiedenen Antigenen undAntiseren
Zusammenfassung: Von sechs verschiedenen Antiseren, die z. T. kommerziell erhältlich sind, wurden die Sequenz-
und Spezies-Spezifität, Affinität und diskfiminätorische Fähigkeit (Unterscheidung der Patienten mit primärem
Hyperparathyreoidismüs von Koiitrollpersonen) mit Hilfe von sechs verschiedenen Hormonen bzw. Hormonfrag-
menten und Serumproben bestimmt. Die Antiseren waren gegen Rinder- oder Schweine-Parathyrin (Parathormon,
PTH) in Meerschweinchen, Kaninchen, Schaf oder Ziege erzeugt worden. Rinder-[125I]Parathyrin diente als Tracer.
Dieses heterqloge Radioimmünoassay-System wies einige Nächteile auf: Die Kreuzreaktivität der Antiseren zu dem
Hormon oder den Hormonfragmenteü im Serum des Menschen war unvollständig (Überlappungsbereich Kontroll-
personen mit Patienten). Wir schließen aus unseren Resultaten und aus Berichten der Literatur, daß ein homologer
Radioimmunoassay fur Parathyrin des Menschen entwickelt werden sollte.
1) Supported by „Deutsche Forschungsgemeinschaft" (Schm 400/1)
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Introduction
Human parathyroid hormone (hPTH)2) is a polypeptide
consisting of 84 amino acid residues. While the amino
acid sequences of positions 1 to 39 and 44 to 84 have
been characterized, there remains disagreement over the
nature of some residues (1). The amino acid sequence of
parathyrin differs among species, and furthermore,
metabolism of this hormone results in the presence of
several fragments within the circulation. In man for
example, the intact hormone, which has a molecular
weight of 9500, represents only a small fraction of the
total immunoreactive parathyrin, whereas carboxy-
terminal fragments of molecular weights from 4500—
7500 daltons are present in concentrations 7 to 20
times greater than the intact hormone (3,4).
Despite the relative predominance of carboxy-te'rminal
fragments, the total concentration of circulating immuno-
reactive PTH in man is low, usually less than 1 μ§/1. Con-
sequently, sequential saturation is employed in most
laboratories to produce an assay system of sufficient
sensitivity to detect circulating immunoreactive PTH in
normal individuals (5, 6, 7). As most antisera have been
produced against bovine parathyrin (bPTH), the io-
dinated bovine hormone will probably exhibit a higher
affinity for pooled antisera than will iodinated hPTH.
Several antigens and antisera for the detection of hPTH
are presently available commercially (9, 10). These
substances however, have not been sufficiently char-
acterized with regard to amino acid sequence, species
specificity, binding of iodinated bPTH, particularly with
respect to iodination damage, affinity, sensitivity for
the detection of hPTH in normal individuals, and their
ability to identify those patients with primary hyper-
parathyroidism. Furthermore, prior to this study, the
influence of different incubation techniques, specifically
equilibrium and sequential saturation or the ability of
these antisera to identify patients with primary hyper-
parathyroidism had not been examined.
Materials and Methods
Antigens
1-84 bPTH highly purified, 200 Mg: Inolex Corporation,
Chicago, Illinois, USA;
1-34 bPTH: Cat. No. 337700, 0.4 mg; Beckman Instruments,
Palo Alto, Ca., USA;
1-34 hPTH: Beckman Instruments, as above;
1-34 hPTH "Boston": obtained from Dr. Henry Keutmann
and Dr. Mike Rosenblatt, Endocrine Unit, Massachusetts General
Hospital, Boston, Ma., USA;
1-34 hPTH "Ciba": distributed by the European-PTH-Study-
Gioup, c/o Prof. R. Ziegler, Dept. Internal Med., Univ. Ulm/
Donau;
53—84 bPTH: obtained from Dr. Henry Keutmann, as above;
2) Abbreviations:
hPTH = humart parathyrin, bPTH = bovine parathyrin,
pPTH = porcine paiathyrin
Antisera
"A VI 2": obtained from Dr. R. Bouillon, Leuven;
"Cal": Cat. No. 869052, lyophilized; lot No. 420056, Cal-
biochem AG, Loewengraben 14, CH-6000 Luzern 5, Switzerland;
"Goat 108" (G 108): obtained by courtesy of Prof. M. Peacock,
MRC Mineral Metabolism, Univ. Leeds, England;
"He 478/ΙΓ and "He 469/VIII": obtained from Dr. Hesch and
Dr. Hehrmann, Med. Hochschule, Karl-Wiechert-Allee 9,
D-3000 Hannover 61;
"211/32": lyophilized, Wellcome Research Laboratories,
Beckenham, Kent, BR3, 3BS, England;
Tracer
12
*iodide: spec. act. 296-555 GBq (8-15 Ci)llsl/mg I, Cat. No.
J 5006, Farbwerke Hoechst AG, D-6000 Frankfurt/Main;
Whatman CF 1 Cellulose: Fa. Horniuth und Vetter, D-6908
Wiesloch; Sephadex G 50: Pharmacia GmbH, Freiburg/Breisgau;
Chloramine T, sodium metabisulfite and other substances were
obtained "pro analysi" by Fa. Merck AG, D-6100 Darmstadt;
Rapid charcoal dispenser: Dosierpumpe Fe 213, B. Braun,
D-3580 Melsungen;
Refrigerated centrifuge: Hettich Roto Silenta K; Fa. Hettich,
D-7200 Tuttlirigen;
Microtiter plates: No. M 220/24 A; Fa. Greiner, D-7440 Niir-
tingen;
Iodination
125iodide is diluted with phosphate buffer, 0.5 mol/1, pH 7.4,
to a concentration of 1 mCi/10 μΐ (= 37 kBq/10 μΐ); bPTH
highly purified (Inolex) is diluted in phosphate buffer 0.06
mol/1, pH 7.4 to 2 Mg/ΙΟ μΐ;
Chloramine Τ is dissolved to 10 mg/ΙΟ ml in phosphate buffer
0.06 mol/1, pH 7.4;
Sodium metabisulfite: 25 mg/ΙΟ ml in phosphate buffer,
0.06 mol/1, pH 7.4;
10 μΐ 125iodide is added to 10 μΐ bPTH and the solution is
placed in an ice-water bath for 2 min. 10 μΐ of icecold chlor-
amine Τ is then added, followed after exactly 15 s, by 50 μΐ of
sodium metabisulfite. The solution is immediately transferred
to a 3 cm Pasteur capillary column (CF 1) and eluted with
2 X 1 ml of phosphate buffer, 0.06 mol/1, pH 7.4. The eluate
containing free iodide is discarded. 2 X 1 ml of hypoparathyroid
serum are pipetted onto the column and fractions containing
10 drops each are collected. 3-4 fractions containing the .
radioactive peak are pooled and about 1/4 is placed on a
Sephadex G 50 column (100 X 1.6 cm); this column is eluted
with pH 3.0 buffer containing 9 g/1 NaCi, 1 g/1 human serum
albumin, 50 mg/1 merthiolate; dextran blue is used as marker
for the void volume. Fractions containing 4 ml are collected
and counted.
Radioimmunoassay
35 μΐ of standard consisting of peptide (as indicated) in hypo-
parathyroid serum or 35 μΐ of patient or control sera are taken
up by a diluter and transferred to a microtiter plate. The diluter
adds 100 μΐ of phosphate buffer, 0.06 mol/1, pH 7.4, containing
1 g/1 human serum albumin, to determine nonspecific binding
(= UB, blank) or 100 μΐ of this buffer containing the antiserum
mentioned. The microtiter plates are incubated 48 h at 4°C.
Tracer (10,000 cpm = 350 Bq, 20 μΐ, spec. act. about 150 Ci/g
= 5.6 TBq/g) is then added by a Hamilton repeating dispenser.
After an additional 48 h at 4°C, 100 μΐ of charcoal (50 g/1
Norit A in phosphate b ffer as above) is added by a rapid
charcoal dispenser. The plates are incubated for l h at 4°C and
centrifuged 10 min X 4000 rpm (r = 17 cm); 200 μΐ of the
supernatant are transferred to counting vials and counted for
5 min.
Results
0
The titers of the antisera were determined by serial
dilution (12). The dilution, at which 1000 cpm (= 35 Bq)
are bound specifically, are shown in table 1:
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Tab. 1. Antiserum code; species immunized and injected anti-
gens are indicated. Working titer represents the dilution
at which 1000 cpm are specifically bound.
antiserum working
code titer
species antigen injected
immunized
A VI 2
Cal
1 : 20,000
50 ml per
vial
guinea pig
rabbit
bPTH, booster
bPTH
hPTH
Goat 108 1 : 5,000 goat
He 478/11 1 : 4,000 sheep
He 469/VIII 1 : 10,000 sheep
bPTH
bPTH, booster pPTH
bPTH, booster pPTH
211/32 1:100,000 guinea pig bPTH
For the determination of sequence and species specifi-
city, the antisera were first incubated with 1—84 bPTH.
The dose-response curves are shown in figure 1.
As can be seen, all antisera recognize 1-84 bPTH. The
greatest sensitivity is found with antiserum A VI 2. To
determine the aminoterminal sequence specificity of all
six antisera, each was incubated separately with four
different synthetic aminoterminal fragments: 1—34
bPTH Beckman, 1-34 hPTH Beckman, 1-34 hPTH
Boston and 1-34 hPTH Ciba. Therefore, 9 standard
dilutions of each peptide with concentrations from
7.8 to 2000 pmol/1 were produced. Only the antisera
Antiserum
28
7.8 15.6 31 62 125 250 500
Bovine parathyrin (1-84) [pmol/l]
1000
Fig. 1. Incubation of six different antisera with bovine parathy-
rin (1-84) for 48 h; thereafter tracer (bovine [ "5I] para-
thyrin) was added and incubation continued for a further
48 h (sequential saturation).
He 469/VIII and He 478/11 were tested with concen-
trations as great as 5000 pmol/1.
Antiserum 211/32 reacts with 1-34 hPTH Boston and
1-34 bPTH Beckman, with a decrease of 33% from
standard zero to standard 2000 pmol/1. 1-34 hPTH Ciba
results in a decrease of 15% from standard zero to stan-
dard 2000 pmol/1. No displacement of tracer occurs
with 1-34 hPTH Beckman in the dilutions zero -
2000 pmol/1. An additional experiment was performed
with antiserum 211/32 and greater peptide concen-
trations (0.1 to 50 nmol/1). 50 nmol/1 of 1-34 hPTH
Boston results in displacement of 60% of tracer from
antiserum 211/32, whereas only 13% of tracer are
displaced by 1-34 hPTH Beckman.
Antiserum Goat 108 reacted only with 1-34 bPTH; a
displacement of only 8% of the tracer was observed. No
other antisera showed any aminoterminal reactivity.
For determination of carboxy-terminal specificity, all
antisera were incubated with 53—84 bPTH obtained by
one of us (H.K.). The results are given in figure 2.
About 90% of the tracer is displaced from antiserum
A VI 2, 40% is displaced from antiserum 211/32, and
minor amounts from antiserum Cal and Goat 108.
Antiserum
63
56
49
35
28
21
14
Col
G108
He469/VHI
211/32
7.8 15:6 31 62 125 250 500
Bovine porothyrin (53-84)(pmol/l)
1000
Fig. 2. Incubation of six different antisera with bovine parathy-
rin (53—84) (sequential saturation).
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Species specificity
As has been shown in figure 1, all antisera recognize the
bovine 1—84 hormone. To determine cross-reactivity of
the antisera to hPTH, serum from a patient with severe
primary hyperparathyroidism was diluted serially with
hypoparathyroid serum. These hPTH serum standard
dilutions were incubated for 48 h with the different
antisera. Bovine [125I]parathyrin was then added and
the incubation continued for 48 h. The results are shown
in figure 3.
Antiserum
6108
0.10 -
1:128 1:16 1:8
Dilution
1:1
Fig. 3. Cross reactivity of the antisera with human serum paia-
thyrin (-fragments). Serum of a patient with severe pri-
mary hyperparathyroidism (serum calcium 4.3 mmol/1)
was diluted serially with parathyrin-free serum. Sequen-
tial saturation.
Binding of iodinated bPTH
Most investigators use gel-filtration chromatography to
separate iodinated hormone from "iodination damage"
and free 125iodide. It is known that different antisera
bind more of the iodinated hormone obtained from the
increasing or decreasing part of the hormone peak. The
behaviour of the six antisera under study towards the
iodinated fractions is shown in figure 4 and 5.
Antiserum Goat 108 not only binds the intact hormone
peak, but also "iodination damage". The increasing part
of the iodinated hormone peak is bound preferentially
by antiserum Goat 108 and He 469/VHI. The increasing
and decreasing part is bound equally by antiserum 211/
32, A VI 2 and He 478/11. The decreasing part is bound
preferentially by antiserum Cal. Unfortunately, in this
experiment (fig. 4) antiserum 211/32 was diluted
1 : 150,000 resulting in less than optimal binding
(1 : 100,000 dilution).
1400 + 28 Antiseren
6108K A Col
1050;
£
.2*700
350-r 7
I
._ . ._ ..
Fraction no.
20 25
Fig.' 4. Gel-filtration on Sephadex G-50 column (90 X 1.6 cm)
of bovine [lisl] parathyrin (1-84). Dextran-blue was
eluted from the column in fractions. 1—3, bovine
[125I]parathyrin (1-84) in fractions 8-15, and "damage"
in fractions 17-28. Each fraction was diluted to
5000 cpm/20 μΐ (= 150 Bq/20 μΐ) and incubated with
antiserum G108, Cal and 211/32 for 48 h to determine
the fractions of highest binding activity.
2100--42
1750--
«g-uoo--
J050--
.S
700--
350-- 7
Antiserum
10 15
Fraction no.
20
Fig. 5. Gel-filtration of bovine [125I]parathydn (1-84) on
Sephadex G-50 column. Conditions as described in
fig. 4. Incubation with antisera A VI 2, He 469/VIII
and He 478/11.
As can be seen in figure 4, ajitiserum Goat 108 binds
the iodinated hormone very well. Because hPTH is not
recognized by this.aritiserum, we subsequently used it
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for "excess antibody" experiments in which the iodinated
hormone peak obtained from the Sephadex G 50 column
is tested for maximal binding (determination of tracer
quality).
bPTH unfortunately becomes structurally altered during
iodination with chloramine T. Only 0.80-0.95 of the
"iodinated hormone" peak obtained from gel-filtration
is bound when antisenim Goat 108 is added in excess
(dilution 1 : 20).
Affinity
The affinity of the six antisera for bovine [125I]parathyrin
was studied according to Scatchard (13). For this
purpose, a serial dilution of bovine [125I]parathyrin was
incubated with the antisera for 48 h. Graphical evaluation
according to Zettner (5) is shown in figure 6.
The Scatchard analysis shown in Figure 6 was calcu-
ated with regard to a maximal binding fraction of 0.80
(antiserum Goat 108 in excess, diluted 1 : 20, bound
only 0.80 of the iodinated hormone). Antisera A VI 2
and Cal displayed a higher bound/free ratio than the
other antisera. Antisera Goat 108 and He 478/H (results
not shown) had a bound/free ratio lower than He
469/VIII and 211/32. The affinity constant is equi-
valent to the negative slope. Because different sub-
populations of antisera exist (varying slopes)9 a linear
regression analysis was not performed.
According to the Scatchard plot and sequence analysis,
antisera A VI 2 and Cal could be useful for the meas-
urement of carboxy-terminal parathyrin-residues. These
results however, give no indication of the clinical use-
fulness of the antisera. This can only be judged from
cross reactivity experiments (Fig. 3) and measurement
of serum samples obtained from definitive healthy
persons and surgically confirmed patients with primary
hyperparathyroidism. Measurement of serum samples
05 1 1.5 2 2.5 3 3.5
Bovine I125]] parathyrin bound [prhol/li
Fig. 6. Affinity of the antisera A VI 2, Cal, He 469/Vttl and
211/3Ϊ plotted according to Scatchard. Results for
antisera G108 and He 478/11 not shown.
obtained from patients with secondary hyperpara-
thyroidism (renal failure) is less suitable for testing the
discriminatory power of an antiserum, because in these
patients very high parathyrin levels are usually observed
and these may be detected even with antisera of medium
quality. Therefore, serum parathyrin levels of 30
healthy persons with a normal serum calcium (2.2-
2.6 mmol/1) and 30 patients with surgically confirmed
primary hyperparathyroidism were measured with all
antisera except antiserum Goat 108 (poor cross reaction
to hPTH) and He 478/11 (insufficient binding). One
patient was excluded because tertiary hyperpara-
thyroidism was misclassified as primary hyperpara-
thyroidism.
The parathyrin concentrations, calculated as pmol/1
(1 pmol/1 is roughly equivalent to 10 ng/1, standard
1-84 bPTH) are plotted as shown for antiserum A VI 2
on figure 7.
In this experiment, circulating parathyrin levels in 16
out of 30 controls were below the limits of detectability
of the system. This may be due to use of the tracer
three weeks after its iodination. In other experiments,
serum parathyrin levels of about 90% of healthy controls
are measurable by antiserum A VI 2.
As is shown in figure 7, the group of patients with
primary hyperparathyroidism is well separated from
healthy controls. However, by measuring only para-
1000
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ϊ
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Jleooα
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§400
1
200
-
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-
-
-
. .
ν
ττ
τ
τ
- / V* ' l· :
. * *ι I ._L_
2.5
Calcium [mmol/U
15
Fig. 7. Serum concentrations of calcium and immunoreactive
parathyrin plotted for antiserum A VI 2, Sequential
saturation technique. Immunoreactive parathyrin in
three patients is in the upper normal range.
ψ primary hyperparathyroidism
• controls
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thyrin, three patients with primary hyperparathyroidism
are in the upper normal range. The comparison of para-
thyrin levels of healthy controls and patients with anti-
serum Cal is shown in figure 8.
The patients with primary hyperparathyroidism are
separated from controls on the basis of serum calcium
levels. However, this discrimination is not achieved by
measuring parathyrin only. As can be seen, a large
overlap between controls and patients occurs. In 15
patients with primary hyperparathyroidism, the concen-
tration of parathyrin is in the normal range. In contrast
to antiserum A VI 2, parathyrin levels in four patients
with primary hyperparathyroidism are too low for meas-
urement.
The parathyrin concentrations obtained by antiserum
He 469/VIII in healthy controls and patients with
primary hyperparathyroidism are shown in figure 9.
Again, a separation of controls from primary hyperpara-
thyroidism is obtained. 23 out of 29 patients with
primary hyperparathyroidism could be distinguished
from controls by measuring parathyrin. The circulating
parathyrin levels of six patients with primary hyperpara-
thyroidism were too low for measurement.
Parathyrin concentrations in healthy controls and
patients with primary hyperparathyroidism as studied
with antiserum 211/32 are shown in figure 10.
1000
S 800
600
200
l 25 3 3.5 A "
Calcium [mmol/i]
Fig. 9. Serum concentrations of calcium and immunoreactive
parathyrin plotted for antiserum He 469/VIII. Sequen-
tial saturation. Separation is achieved by measuring
immunoreactive parathyrin in 23 of 29 patients.
v primary hyperparathyroidism
• controls
1000-
1800
i.
1600
200
*
τ
τ
l 2.5 3 35 4
Calcium [mmol/l]
Fig. 8. Serum concentrations of calcium and immunoreactive
parathyrin plotted for antiserum Cal. Sequential satura-
tion. Separation is not achieved by measuring immuno-
reactive parathyrin only,
τ primary hyperparathyroidism
• controls
1000
r 600
'
1400
200
3 3.5
Calcium [m mol/l]
Fig. 10. Serum concentrations of calcium and immunoreactive
parathyrin plotted for antiserum 211/32. Sequential
saturation technique. Separation is achieved by
measuring immunoreactive parathyrin in 22 of 29
patients.
τ primary hyperparathyroidism
• controls
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Again, a separation of controls from primary hyperpara-
thyroidism is obtained. 22 out of 29 patients with primary
hyperparathyroidism are distinguished from controls by
measuring parathyrin alone. The serum levels of seven
patients with primary hyperparathyroidism are too low
for measurement.
Equilibrium technique
During review of the literature, we were impressed by
the fact that the only group using equilibrium conditions
for the incubation of tracer and standards or unknown
samples, respectively, reports a large overlap of controls
and patients with primary hyperparathyroidism (14). To
our knowledge the influence of equilibrium or sequential
saturation on the discriminatory power of antisera has
not been determined. Therefore controls and patients
with primary hyperparathyroidism were measured with
two antisera with the equilibrium and the sequential
saturation technique. Under equilibrium conditions the
overlap increased: antiserum He 469/VIII detected
elevated serum parathyrin concentrations in 80% (by
sequential saturation) and in 63% (by equilibrium) of
patients with primary hyperparathyroidism. Antiserum
A VI 2 showed elevated parathyrin concentrations in
90% of these patients by sequential saturation and in
84% by equilibrium. Therefore, routine assays for para-
thyrin should be run under conditions of sequential
saturation.
Imprecision
Some overlap is produced by the imprecision inherent
in radioimmunoassay. The „intra"-assay coefficient of
variation (CV) in the steepest part of the standard curve
(highest precision) is 6.1 % (n = 22 triplicates of one
serum, mean 249 pmol/1, standard deviation 15.1 pmol/1)
for antiserum A VI 2. We also determined the "inter"-
assay CV and the accuracy. The serum of a patient with
surgical hypoparathyroidism, who was treated with
vitamin D and calcium, was supplemented with 1—84
bPTH to a concentration of 111 pmol/1. This "control
serum 111" was measured in triplicate in 34 different
assays (= a period of 34 weeks). A mean of 123 pmol/1
was obtained with a standard deviation of 15.7 and a
CV of 12.7%.
Discussion
Many antisera used for the radipiminunQassay of para-
thyrin are poorly characterized with respect to sequence
specificity.
Antiserum A VI 2
This antiserum is regarded as carboxy-terminal in spec-
ificity (11). Using A Vl 2,Bouillon observed no displace-
ment of bovine [125I]parathyrin 1—84 in experiments
with 1-34 bPTH. Furthermore, he obtained smaller
increases of immunoreactive parathyrin in serum with
A VI 2 during EDTA-infusion than with antiserum
211/32. He did not report experiments with 1-34
hPTH and 53-84 bPTH. We observe no displacement
with 1-34 hPTH and nearly total displacement of
tracer with 53-84 bPTH. We therefore conclude that
antiserum A VI 2 is entirely carboxy-terminal in
specificity. We suggest that there is no reactivity with
the medium part of the parathyrin sequence from amino
acid residues 35-52. As is reflected by the steepness
of the standard curves, the affinity determined according
to Scatchard (13) is high in comparison with the other
antisera. This antiserum may be used clinically, as nearly
complete separation between controls and patients
with primary hyperparathyroidism is achieved by meas-
uring parathyrin in alone (11). We found a high degree of
cross reactivity to hPTH or hPTH fragments in serum.
Antiserum Cal
We used the titer of this antiserum which the manufac-
turer recommends. Therefore, we achieved more
binding with antiserum Cal than with other antisera. As
far as we could determine, no data concerning sequence
specificity of this antiserum exist. We observed no
displacement of tracer with different 1—34 peptides
and a small displacement with 53—84 bPTH. There may
exist some reactivity with that part of the parathyrin
molecule corresponding to amino acid residues 35—52.
However, while affinity according to Scatchard (13) is
high in comparison to the other antisera, this antiserum
is of restricted clinical use because there is considerable
overlap between controls and patients with primary
hyperparathyroidism.
Antiserum Goat 108
This antiserum reacts partly with both the amino- and
carboxy-terminal portions of parathyrin. In addition,
there may be some reactivity with the portion of the
molecule corresponding to amino acid residues 35—52.
1-34 bPTH and 53-84 bPTH are not able to displace
bovine [125I]parathyrin 1-84 in amounts comparable
to the intact 1-84 bPTH.
Affinity according to Scatchard is low in comparison
with A VI 2 and Cal. Goat 108 may be used for purif-
ication of tracer according to the method ofSchopman
(15) or for quality control of the labelled hormone
(excess antibody experiments, estimation of maximal
binding).
Antiserum He 469/VIII
This antiserum is regarded as carboxy-terminal in
specificity and its clinical usefulness has been demon-
strated by Hehrmann et al. (16). However, the number
of patients they investigated was small (9 patients with
primary hyperparathyroidism). In our experiments, we
observed no displacement with 1—34 peptides and only
J. Clin. Chem. Clin. Biochem. / Vol. 16,1978 / No. 5
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a small displacement of tracer with 53-84 bPTH. How-
ever, this antiserum was elicited against bovine and
porcine parathyrin; consequently our results with the
bovine fragments may not reflect the sequence specif-
icity. The affinity determined according to Scatchard is
lower than the affinity of A VI 2 or Cal, which is
reflected in dose-response curves less steep than with
A VI 2 or Cal. While the antiserum may be used clinic-
ally, slightly increased serum levels of parathyrin are
not detected. Perhaps, by increasing the serum volume
from 35 μΐ to 50 or 100 μΐ, better discriminatory power
may be achieved. For our radioimmunoassay of para^
thyrin we chose a serum volume of 35 μΐ, because non-
specific binding with this small volume was low and the
same with all serum samples. Due to insufficient binding,
no experiments were performed with antiserum He 478/
II with respect to clinical usefulness. In other laboratories,
sufficient binding and discrimination between controls
and patients has been achieved with a later bleeding
(He 478/VI, personal communication).
Antiserum 211/32
Several experiments have been reported using antiserum
211/32. With 1-34 bPTH, more than 50% of the label
is displaced (9, 10,11, 17). Furthermore it was shown
that circulating immunoreactive parathyrin after para-
thyroidectomy rapidly decreased (half-life of 10-15 min)
using 211/32 (10). As we reported earlier, the initial
half life of parathyrin in human plasma after removal of
parathyroid adenomas was 10—20 min as measured by
the same antiserum. Further results using different 1—34
hPTH peptides have, to our knowledge, not been
reported. Woo observed some 10—15% decrease of
binding using the 53—84 fragment of bPTH. In our
experiments, 1-34 bPTH displaces 60% of labelled 1-84
bPTH, and the 53-84 bPTH fragment displaces 40% of
the tracer. We conclude that the mid-portion of the para-
thyrin-molecule is not recognized by this antiserum.
211/32 is mainly directed towards the ammo-terminal
portion of parathyrin.
The structure of the human 1—34 peptide synthesized
by the Boston group is nearly as effective as the bovine
1-34 in displacing the bovine [125I]parathyrin 1-84.
However, the structure synthesized by Ciba or Beckman
is less effective. It is premature to conclude which syn-
thetic peptide most resembles that of man. It is suggested
that the 1—34 hPTH Boston is more effective because it
is more similar to the bovine structure.
The affinity of antiserum 211/32 determined according
to Scatchard is lower than the affinity of antiserum A VI
2 or Cal. Antiserum 211/32 may be used clinically
because sufficient separation of controls from patients
with primary hyperparathyroidism is achieved. An over-
lap of controls with primary hyperparathyroidism was
also reported by Bouillon (11), Kleerekooper (10) and
Woo (9). This antiserum is now used by us for locali-
zation of parathyroid adenomas by measurement of
native parathyrin in samples obtained from venous
catheterization of the neck.
Antigens
Obviously there is no problem in eliciting antisera against
the different peptides mentioned. With 1-84 bPTH we
were able to produce antisera in each of 15 guinea pigs
(unpublished results). Using 1-84 bPTH, Arnaud (6)
reported the production of antisera of low cross-reactiv-
ity to hPTH in most animals. The antisera reported here,
which were produced against bPTH (Cal, Goat 108,
211/32) either could not discriminate patients from
controls completely (Cal, 211/32) or cross-reacted poorly
(Goat 108).
The immunoreactivity of the 1—34 peptides differs
markedly from that of the 1—84 peptides. Antisera have
been raised successfully against 1—34 hPTH Boston and
1-34 hPTH Ciba (18). One antiserum ("G 127")
elicited against 1—34 hPTH Boston reacted less with
1-84 hPTH than with the 1-34 antigen (19). This
difference in reactivity might be caused by
a) an error in the sequence of the 1—34 peptide or
b) ammo-terminal conformational changes induced by
the amino acids 35—84.
Another antiserum ("G 199"), which was raised against
1—84 bPTH and which reacts mainly with the amino-
terminal, did not discriminate between intact hPTH and
1-34 hPTH Boston, whereas 1-34 hPTH Ciba showed
little cross reactivity. Our own results obtained with
antiserum 211/32 point to the fact that 1-34 hPTH
Boston resembles the bovine structure more closely.
This 1—34 peptide was much more effective in displacing
the bovine [125I]parathyrin 1—84. Our results, like the
data reported on antiserum G 199 (19), would support
the 1-34 hPTH Boston structure: antiserum 211/32
recognizes the intact human hormone and the 1—34
hPTH Boston.
The small difference of 3 amino acids between 1—34
hPTH Boston and 1-34 hPTH Ciba alters the immuno-
reactivity drastically, as reported by Visser et al (18).
These investigators immunized rabbits against 1-34
hPTH Ciba. The antisera of these animals cross-reacted
apparently 100-fold less with 1-34 hPTH Boston or
1-84 hPTH than with 1-34 hPTH Ciba.
The serum from sheep immunized with pPTH (He
469/VIII) does not completely separate patients with
primary hyperparathyroidism from controls. The -serum
of the only animal immunized with hPTH (adenoma
extract) discriminates between patients with primary
hyperparathyroidism and controls. It has to be noted
that our results were obtained from a single serum
specimen of patients or controls. In practice, most often
two or three samples are analyzed from patients sus-
pected of having primary hyperparathyroidism. As has
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been shown by Almqvist (14), this will improve diagnostic
accuracy substantially. More than 100 patients with
primary hyperparathyroidisrn are now diagnosed by
means of the radioimmunoassay for parathyrin with
antiserum A VI 2 and serum calcium determination.
It is concluded from these results that a radioimmuno-
assay for hPTH, employing antiserum against hPTH,
human [125I]parathyrin (or analogs with certain sub-
stituted amino acids for better labelling) and hPTH
standards, should be developed in the future. This
could further improve the value of parathyrin deter-
mination.
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